Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
24 hedge funds and large institutions have $9.55M invested in Amplify Treatments, Testing and Advancements ETF in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 4 closing their positions.
3% more capital invested
Capital invested by funds: $9.29M → $9.55M (+$259K)
4% less funds holding
Funds holding: 25 → 24 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.17M |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$401K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$60.6K |
| 4 |
LF
Lee Financial
Dallas,
Texas
|
+$49.5K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
+$26.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
G
Gainplan
Bloomfield Hills,
Michigan
|
-$732K |
| 2 |
Belvedere Trading
Chicago,
Illinois
|
-$410K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$135K |
| 4 |
Jane Street
New York
|
-$99.4K |
| 5 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$80K |
GERM Hedge Fund Activity: Q3 2021 in Review
24 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q3 2021, worth a combined $9.55M — up 2.8% from $9.29M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GERM and 3 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 4 added.
The largest buyer was Goldman Sachs, adding an estimated $1.17M. The largest seller was Gainplan, cutting an estimated $732K.
- 24 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q3 2021, down from 25 in Q2 2021.
- Funds reported $9.55M of Amplify Treatments, Testing and Advancements ETF stock for Q3 2021, up 2.8% quarter-over-quarter.
- 3 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q3 2021 and 4 closed out, a net change of -1 holder.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q3 2021 was Goldman Sachs, an estimated $1.17M added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q3 2021 was Gainplan, an estimated $732K sold.
Based on aggregated 13F filings for Q3 2021.